Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1859 • ACR Convergence 2024
Clonal Relationships Between Tph and Tfh Cells in Patients with SLE and in Murine Lupus
Takanori Sasaki¹, John Sowerby², Yinan Xiao², Runci Wang², Pui Lee³, Yujie Qu⁴, Marc Sze⁴, Stephen Alves⁴, Marc Levesque⁴, Karen Costenbader⁵ and Deepak Rao⁶, ¹Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Boston Children's Hospital, Newton, MA, ⁴Merck & Co., Inc., Boston, MA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T helper cells, including T peripheral helper (Tph) cells and T follicular helper (Tfh) cells, play pivotal roles in promoting B cell activation and…
Abstract Number: 2160 • ACR Convergence 2024
Development of a Lupus Chatbot
Leila Khalili¹, Pooja Desai², Maya Souvignier¹, Sophie Askanase², Lena Mamykina² and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²CUIMC, New York, NY
Background/Purpose: Artificial Intelligence (AI) is poised to take the world of medicine by storm. The next decade will likely bring major changes in technology use…
Abstract Number: 2381 • ACR Convergence 2024
Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database
Kishan Patel¹, Shivang Chaudhary², Simran Bhimani³, Yash Deshpande³, Leighton Hope² and Chaitanya Rojulpote², ¹Riverside Community Hospital, Riverside, CA, ²Saint Louis University, St. Louis, MO, ³The Wright Center for graduate medical education, Scranton, PA
Background/Purpose: Lupus nephritis (LN) is a complication of systemic lupus erythematosus (SLE) that occurs in 50 percent of patients. LN serves as an important predictor…
Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Melissa Fazzari¹, Jane Salmon², Marta Guerra², Nathalie Costedoat-Chalumeau³, Veronique LE GUERN⁴, Gaëlle Guettrot-Imbert⁴, Marta Mosca⁵, Dina Zucchi⁶, Chiara Tani⁷, Rebecca Fischer-Betz⁸, Isabell Haase⁹, Anna Broder¹⁰, Navneet Kaur¹¹, Jill Buyon¹², Brooke Cohen¹², Diane Kamen¹³, Jessica English¹⁴, Anna Arar¹³ and Mimi Kim¹⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²Hospital for Special Surgery, New York, NY, ³Inserm DR Paris 5, Paris, France, ⁴Cochin hospital, Paris, France, ⁵University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Italy, ⁸Uniklinik Düsseldorf, Düsseldorf, Germany, ⁹Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, ¹⁰Hackensack Network, Hackensack, NJ, ¹¹Touro University Medical Group, Sacramento, CA, ¹²NYU Grossman School of Medicine, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴Medical University of South Carolina, Johns Island, SC, ¹⁵Albert Einstein College of Medicine, Larchmont, NY
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…
Abstract Number: 2417 • ACR Convergence 2024
Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America
Romina Nieto¹, Lucia Hernandez², Marina Scolnik³, Gisela Constanza Subils⁴, Veronica Saurit⁵, Verónica Gabriela Savio⁶, Valeria Arturi⁷, Boris Kisluk⁸, Luciana González Lucero⁹, Wilfredo Patiño Grageda¹⁰, María De Los Ángeles Gargiulo¹¹, ODIRLEI MONTICIELO¹², Angela Duarte¹³, Eduardo Borba¹⁴, Luciana Parente¹⁴, Edgard Reis Neto¹⁵, Oscar Neira¹⁶, Gustavo Aroca Martínez¹⁷, Antonio Iglesias Gamarra¹⁸, Paul Méndez-Patarroyo¹⁹, Rafael López²⁰, Margarita Portela Hernandez²¹, Carlos Núñez-Álvarez²², Yelitza González Bello²³, Jorge Isaac Velasco Santos²⁴, Jorge Esquivel-Valerio²⁵, Marcos Vázquez²⁶, Maria Teresa Martinez de Filartiga²⁷, Magaly Alva Linares²⁸, Roberto Muñoz Louis²⁹, Carina Pizzarossa³⁰, Ana Carolina Ralle³¹, María Camila Riascos³², Joaquín Martínez Serventi³³, Graciela Alarcon³⁴, Bernardo Pons-Estel² and Guillermo Pons-Estel³⁵, and Grupo Latinoamericano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Córdoba, Argentina, ⁵hospital privado universitario de cordoba, Córdoba, Argentina, ⁶Sección de Reumatología, Hospital Córdoba, Córdoba, Argentina, ⁷Hospital HIGA San Martín, La Plata, Argentina, ⁸Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, ⁹Hospital Padilla, Tucumán, Argentina, ¹⁰Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹¹Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹³Universidad Federal de Pernambuco, Pernambuco, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil, ¹⁶Hospital del Salvador, Santiago de Chile, Chile, ¹⁷Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ¹⁸Clínica de La Costa - Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, ¹⁹Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²⁰Servicio de Reumatología. Hospital Luís Vernaza, Guayaquil, Ecuador, Guayaquil, Ecuador, ²¹Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, ²²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ²³Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, ²⁴Hospital Central Dr. Ignacio Morones Prieto, Potosí, Mexico, ²⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ²⁶Hospital de Clínicas I, Asunción, Paraguay, Asuncion del Paraguay, Paraguay, ²⁷Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, ²⁸Servicio de Reumatologia. Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, ²⁹Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ³⁰Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ³¹Hospital Señor del Milagro, Salta, Argentina, ³²Centro de Referencia en Osteoporosis & Reumatología, Cali, Colombia, ³³Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, CABA, Argentina, ³⁴The University of Alabama at Birmingham, Oakland, CA, ³⁵Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with complex multi-systemic involvement. Herpes zoster (HZ) is caused by the reactivation of latent varicella-zoster virus…
Abstract Number: 2434 • ACR Convergence 2024
ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
Nicole Narayan¹, Joshua Hoffman², Claire Langrish¹, Sibel Ucpinar³, Pedro Corpuz³, Barbara Mittleman⁴ and Mera Tilley², ¹Alumis, South San Francisco, CA, ²Alumis Inc, South San Francisco, CA, ³Alumis, South San Francisco, ⁴Alumis, Inc., San Francisco, CA
Background/Purpose: ESK-001 is a potent, highly selective, oral, allosteric small molecule inhibitor of TYK2 currently being investigated in adults with active SLE in the LUMUS…
Abstract Number: 2580 • ACR Convergence 2024
Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Eduardo Mysler¹, Stanislav Ignatenko², Alexander Gordienko³, Josefina Cortés-Hernández⁴, Nancy Agmon-Levin⁵, Pongthorn Narongroeknawin⁶, Katarzyna Romanowska-Prochnicka⁷, Nan Shen⁸, Hana Ciferská⁹, Masanari Kodera¹⁰, James Cheng-Chung Wei¹¹, Piotr Leszczynski¹², Joung Liang Lan¹³, Rafał Wojciechowski¹⁴, Tunde Tarr¹⁵, Elena Vishneva¹⁶, Yi-Hsing Chen¹⁷, Yuko Kaneko¹⁸, Stephanie Finzel¹⁹, Alberta Hoi²⁰, Masato Okada²¹, Ajchara Koolvisoot²², Shin-Seok Lee²³, Lie Dai²⁴, Hiroshi Kaneko²⁵, Bernadette Rojkovich²⁶, Lingyun Sun²⁷, Eugeny Zotkin²⁸, Jean-François Viallard²⁹, Berta Paula Magallares³⁰, Tirtha Sengupta³¹, Carole Sips³², Carole Lau³³, Alexandre Avrameas³² and Stephen J Oliver³⁴, ¹Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ²Charité Research Organisation, GmbH, Berlin, DE, Berlin, Germany, ³SM Kirov Military Medical Academy, St Petersburg, RU, St Petersburg, Russia, ⁴Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ⁵Center for Autoimmune Disease, Sheba Medical Center, Tel Aviv University, Tel Aviv, IL, Tel Aviv, Israel, ⁶Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, TH, Bankok, Thailand, ⁷Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, PL, Warsaw, Poland, ⁸Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), ⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, CZ, Prague, Czech Republic, ¹⁰Department of Dermatology, Japan Community Healthcare Organization, Chukyo Hospital, Nagoya, JP, Nagoya, Japan, ¹¹Department of Rheumatology, Chung Shan Medical University Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹²Department of Internal Medicine, Poznan University of Medicine Sciences, Poznan, PL, Poznan, Poland, ¹³Rheumatology and Immunology Center, China Medical University Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹⁴Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, PL, Bydgoszcz, Poland, ¹⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, HU, Debrecen, Hungary, ¹⁶LLC Family Clinic, Yekaterinburg, RU, Yekaterinburg, Russia, ¹⁷Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan, ¹⁹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, DE, Freiburg im Breisgau, Germany, ²⁰Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ²¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, JP, Tokyo, Japan, ²²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, Bangkok, Thailand, ²³Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea, ²⁴Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN, Guangzhou, China (People's Republic), ²⁵Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, JP, Tokyo, Japan, ²⁶Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, HU, Budapest, Hungary, ²⁷Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), ²⁸V A Nasonova Research Institute of Rheumatology, Moscow, RU, Moscow, Russia, ²⁹CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FR, Bordeaux, France, ³⁰Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain, ³¹Novartis Pharma India, Hyderabad, IN, Hyderabad, India, ³²Novartis Pharma AG, Basel, CH, Basel, Switzerland, ³³Novartis Pharma, East Hanover, NJ, USA, East Hanover, ³⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736) is an afucosylated, fully human IgG1 monoclonal antibody with a dual mechanism of action of enhanced B-cell depletion through antibody-dependent cellular cytotoxicity…
Abstract Number: 2677 • ACR Convergence 2024
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Joy Park¹, Lanlan Ji¹, Jorge Cabezas¹, Xiaojing Wang², Bryan Blaker¹, Dilip Rao¹, Aparna Godavarthy¹, Lucero Blaker¹, FNU Ruchi¹, Ioana Coman¹, Nancy Olsen³, Joshua Lewis², Mariko Ishimori⁴, Kyriakos Kirou⁵, Christina Donath¹, Sara Kahlown⁶, Damira Sereda¹, Marlene Marte Furment¹, Sandy Nasr⁷, Sravani Lokineni¹, rosalind Ramsey-Goldman⁸, Michael Weisman⁹, Arthur Weinstein¹⁰, Cynthia Aranow¹¹, Banki Katalin¹², Michael McDermott¹³, Daniel Wallace¹⁴ and Andras Perl¹, ¹SUNY, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³Penn State University/Milton S Hershey, Hershey, PA, ⁴Cedars-Sinai Health System, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ⁷SUNY Upstate University Hospital, syracuse, NY, ⁸Northwestern University, Chicago, IL, ⁹Stanford University, Los Angeles, CA, ¹⁰Georgetown University, Pasadena, CA, ¹¹Feinstein Institutes for Medical Research, New York, NY, ¹²SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ¹³University of Rochester, Rochester, NY, ¹⁴Cedars Sinai, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with significant mortality attributed to infections due to toxicity of immunosuppressant medications. Our…
Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…
Abstract Number: 0119 • ACR Convergence 2024
Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis
Basant Elnady¹, Ziyad Alakkas², Sultana Abdulaziz³, Hussain Halabi⁴, Ahmed A. G. Ibrahim⁵, Hoda E. Draz⁵, Mohammed Attar⁶, Hassan Daghasi⁷, Abeer Alhalwani⁸, Reman Shaker⁹ and Ghadeer Maher Elsheikh¹⁰, ¹Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, ²King Faisal Medical Complex, Taif, Saudi Arabia, ³King Fahad Hospital, Jeddah, Saudi Arabia, ⁴King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, ⁵Benha University, Benha, Egypt, ⁶al hada armed forces hospital, Taif, Saudi Arabia, ⁷Alhada military hospital, Taif, Saudi Arabia, ⁸East Jeddah hospital, Jeddah, Saudi Arabia, ⁹King Faisal Specialist Hospital and Research centre, Jeddah, Saudi Arabia, ¹⁰Menoufia University, Menoufia, Egypt
Background/Purpose: Antiphospholipid syndrome (APS) is closely linked with Systemic Lupus erythematosus (SLE) and can influence patient outcomes. The interplay between APS and SLE, including the evolution…
Abstract Number: 0182 • ACR Convergence 2024
Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Patricia Nogueira De Sa¹, Stephanie Wirtshafter¹, Abdallah Geara² and Kimberly DeQuattro², ¹University of Pennsylvania, Pennsylvania, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune condition that disproportionally affects individuals from racial and ethnic minority groups with more than 95%…
Abstract Number: 0217 • ACR Convergence 2024
Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds
Joy Buie¹, Safoah Agyemang¹ and Joan Merrill², ¹Lupus Foundation of America, Washington, DC, ²Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …
Abstract Number: 0430 • ACR Convergence 2024
Clues from Early Gestational Mean Arterial Pressure in Predicting Preeclampsia Risk in Systemic Lupus Erythematosus (SLE)
Rashmi Dhital¹, Dilli Poudel² and Ukachi Emeruwa³, ¹UC San Diego, Brentwood, TN, ²Vanderbilt University, Nashville, TN, Brentwood, TN, ³UC San Diego, San Diego
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a known risk factor for chronic hypertension (cHTN) as well as preeclampsia. While the role of cHTN is known,…
Abstract Number: 0612 • ACR Convergence 2024
Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
Nevin Hammam¹, Ahmed Elsaman², Esam Abualfadl³, Soha Senara⁴, Nada M. Gamal⁵, Mona H. Abd Elsamea⁵, Abdelhfeez Moshrif⁶, Samar Tharwat⁷, Osman Hammam⁸ and Tamer A Gheita⁹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; Qena/Luxor Hospitals, Qena, Egypt, Sohag, Egypt, ⁴Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Assiut, Egypt, ⁶Al-azhar university, Assiut, Egypt, ⁷Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁸Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a great heterogeneity and unpredictable flare. In managing patients with SLE, the diagnosis…
Abstract Number: 0630 • ACR Convergence 2024
Lupus Lymphocyte Activation Score of Pathologic T and B Cell Phenotypes Increased in Patients at Risk of Systemic Lupus Erythematosus
Alice Horisberger¹, Ifeoluwakiisi Adejorin², Julia Caldropoli³, Eilish Dillon⁴, Emily Oakes⁵, Kathryne Marks⁵, Takanori Sasaki⁶, Karen Costenbader⁷ and Deepak Rao⁴, ¹Brigham and Woman's Hospital, Harvard Medical School, Lausanne, Switzerland, ²Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, Switzerland, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: In systemic lupus erythematosus (SLE), loss of self-tolerance and pathologic T and B cell interactions lead to autoantibodies against nuclear antigens (ANA) production. In…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].